TY - JOUR
T1 - Asymmetric post-translational modifications regulate the nuclear translocation of STAT3 homodimers in response to leukemia inhibitory factor
AU - Diallo, Mickael
AU - Pimenta, Constança
AU - Murtinheira, Fernanda
AU - Martins-Alves, Daniela
AU - Pinto, Francisco R.
AU - da Costa, André Abrantes
AU - Letra-Vilela, Ricardo
AU - Martin, Vanesa
AU - Rodriguez, Carmen
AU - Rodrigues, Mário S.
AU - Herrera, Federico
N1 - Funding Information:
We acknowledge the BioISI/FCUL Microscopy Facility, a node of the Portuguese Platform of BioImaging supported by FEDER funds (Ref. PPBI-POCI-01-0145-FEDER-022122). The mass spectrometry-based proteomics approach was performed at the i3S Proteomics Scientific Platform with the assistance of Hugo Osório, and had support from the Portuguese Mass Spectrometry Network, integrated in the National Roadmap of Research Infrastructures of Strategic Relevance (ROTEIRO/0028/2013; LISBOA-01-0145-FEDER-022125). FH was supported by Project LISBOA-01-0145-FEDER-007660 (Cellular Structural and Molecular Microbiology) funded by FEDER funds through COMPETE2020 – Programa Operacional Competitividade e Internacionalização (POCI). FH, FRP and MSR were supported by Centre grants from Fundação para a Ciência e Tecnologia to the BioISI Research Unit (Refs. UIDB/04046/2020 and UIDP/04046/2020, https://doi.org/10.54499/UIDB/04046/2020 ) and by individual grants through Fundação para a Ciência e Tecnologia (PTDC/MED-NEU/31417/2017 to FH and PTDC/FIS-MAC/2741/2021 to MSR, https://doi.org/10.54499/PTDC/FIS-MAC/2741/2021 ). MD was supported by a research contract under FCT grant Ref. PTDC/MED-NEU/31417/2017. RV, FM and AAC were supported by PhD fellowships from Fundação para a Ciência e Tecnologia (Refs. PD/BD/128163/2016, SFRH/BD/133220/2017 and UI/BD/153051/2022, respectively). Funded by the European Union (TWIN2PIPSA, GA 101079147). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.
Funding Information:
We acknowledge the BioISI/FCUL Microscopy Facility, a node of the Portuguese Platform of BioImaging supported by FEDER funds (Ref. PPBI-POCI-01-0145-FEDER-022122). Mass spectrometry was carried out with support from the Portuguese Mass Spectrometry Network, integrated in the National Roadmap of Research Infrastructures of Strategic Relevance (ROTEIRO/0028/2013; LISBOA-01-0145-FEDER-022125). FH was supported by Project LISBOA-01-0145-FEDER-007660 (Cellular Structural and Molecular Microbiology) funded by FEDER funds through COMPETE2020 – Programa Operacional Competitividade e Internacionalização (POCI). FH, FRP and MSR were supported by Centre grants from Fundação para a Ciência e Tecnologia to the BioISI Research Unit (Refs. UIDB/04046/2020 and UIDP/04046/2020, https://doi.org/10.54499/UIDB/04046/2020 ) and by individual grants through Fundação para a Ciência e Tecnologia (PTDC/MED-NEU/31417/2017 to FH and PTDC/FIS-MAC/2741/2021 to MSR, https://doi.org/10.54499/PTDC/FIS-MAC/2741/2021 ). MD was supported by a research contract under FCT grant Ref. PTDC/MED-NEU/31417/2017. RV, FM and AAC were supported by PhD fellowships from Fundação para a Ciência e Tecnologia (Refs. PD/BD/128163/2016, SFRH/BD/133220/2017 and UI/BD/153051/2022, respectively). Funded by the European Union (TWIN2PIPSA, GA 101079147). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.
Publisher Copyright:
© The Author(s) 2023.
PY - 2023/12/27
Y1 - 2023/12/27
N2 - STAT3 is a pleiotropic transcription factor overactivated in 70% of solid tumours. We have recently reported that inactivating mutations on residues susceptible to post-translational modifications (PTMs) in only one of the monomers (i.e. asymmetric) caused changes in the cellular distribution of STAT3 homodimers. Here, we used more controlled experimental conditions, i.e. without the interference of endogenous STAT3 (STAT3-/- HeLa cells) and in the presence of a defined cytokine stimulus (Leukemia Inhibitory Factor, LIF), to provide further evidence that asymmetric PTMs affect the nuclear translocation of STAT3 homodimers. Time-lapse microscopy for 20 min after LIF stimulation showed that S727 dephosphorylation (S727A) and K685 inactivation (K685R) slightly enhanced the nuclear translocation of STAT3 homodimers, while K49 inactivation (K49R) delayed STAT3 nuclear translocation. Our findings suggest that asymmetrically modified STAT3 homodimers could be a new level of STAT3 regulation and, therefore, a potential target for cancer therapy.
AB - STAT3 is a pleiotropic transcription factor overactivated in 70% of solid tumours. We have recently reported that inactivating mutations on residues susceptible to post-translational modifications (PTMs) in only one of the monomers (i.e. asymmetric) caused changes in the cellular distribution of STAT3 homodimers. Here, we used more controlled experimental conditions, i.e. without the interference of endogenous STAT3 (STAT3-/- HeLa cells) and in the presence of a defined cytokine stimulus (Leukemia Inhibitory Factor, LIF), to provide further evidence that asymmetric PTMs affect the nuclear translocation of STAT3 homodimers. Time-lapse microscopy for 20 min after LIF stimulation showed that S727 dephosphorylation (S727A) and K685 inactivation (K685R) slightly enhanced the nuclear translocation of STAT3 homodimers, while K49 inactivation (K49R) delayed STAT3 nuclear translocation. Our findings suggest that asymmetrically modified STAT3 homodimers could be a new level of STAT3 regulation and, therefore, a potential target for cancer therapy.
KW - Homodimerization
KW - Leukemia inhibitory factor
KW - Post-translational modifications
KW - STAT3
UR - http://www.scopus.com/inward/record.url?scp=85180667245&partnerID=8YFLogxK
U2 - 10.1007/s13402-023-00911-9
DO - 10.1007/s13402-023-00911-9
M3 - Article
AN - SCOPUS:85180667245
SN - 2211-3428
VL - 47
SP - 1065
EP - 1070
JO - Cellular Oncology
JF - Cellular Oncology
IS - 3
ER -
